Titan cuts jobs to focus on Probuphine
This article was originally published in Scrip
Executive Summary
Titan Pharmaceuticals is reducing its workforce by 40% to focus on its most clinically advanced product, Probuphine (buprenorphine in an ethylene-vinyl acetate rod), for the treatment of opioid addiction.